Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Addition of elotuzumab to backbone treatment regimens for multiple myeloma: An updated meta-analysis of randomized clinical trials
    Journal Article

    Costa, B. A.; Costa, T. A.; Chagas, G. C. L.; Mouhieddine, T. H.; Richter, J.; Usmani, S. Z.; Mailankody, S.; Rajeeve, S.; Hashmi, H.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: A secondary SWOG analysis
    Journal Article

    Banerjee, R.; Sexton, R.; Cowan, A. J.; Rosenberg, A. S.; Ailawadhi, S.; Rajkumar, S. V.; Kumar, S.; Dispenzieri, A.; Lonial, S.; Durie, B. G. M.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • A phase III randomized trial for frail newly diagnosed multiple myeloma patients comparing bortezomib-lenalidomide-dexamethasone (VRd-lite followed by len maintenance) with daratumumab-lenalidomide-dexamethasone (DRd followed by len+/- dara maintenance): SWOG S2209
    Meeting Abstract

    Ailawadhi, S.; Hoering, A.; Ye, J. C.; Lipe, B.; Chauncey, T. R.; Gowin, K.; Calverley, D.; Holstein, S. A.; Campagnaro, E. L.; Rosenthal, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term follow-up of real-world teclistamab therapy for relapsed/refractory multiple myeloma from the IMWG Immunotherapy Working Group Committee
    Meeting Abstract

    Tan, C. R.; Asoori, S.; Nemirovsky, D.; Derkach, A.; Brunaldi, L.; Popat, R.; Lau, C.; Kastritis, E.; Martínez-Lopez, J.; Bansal, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mutationally enriched regions of the non-coding genome harbor functionally impactful mutations that dysregulate key genes involved in multiple myeloma pathogenesis
    Meeting Abstract

    Blaney, P.; Maclachlan, K. H.; Papadimitriou, M.; Mikulasova, A.; Gagler, D. C.; Braunstein, M. J.; Lahoud, O. B.; Kaminetzky, D.; Wang, Y.; Liu, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world characteristics and treatment patterns of transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) as front-line treatment: Results from a multicenter chart review study
    Meeting Abstract

    Tan, C. R.; Gordan, L.; Dileo, R.; Mewawalla, P.; Larson, S. M.; Davies, F. E.; Oveisi, D.; Gupta-Werner, N.; Medhekar, R.; Cortoos, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Racial differences in proportion of myeloma cases attributable to modifiable risk factors in the United States, 2016-21
    Meeting Abstract

    Anuraj, A.; Rath, D.; Derkach, A.; Usmani, S. Z.; Shah, U. A.
    Blood (2024)

    Fulltext@MSK | Save
  • First results from the dose escalation part of the phase 1 study of KTX1001, an oral, first-in-class, potent inhibitor of MMSET/NSD2 for relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Bories, P.; Gasparetto, C.; Dingli, D.; Lonial, S.; Usmani, S. Z.; Berdeja, J. G.; Chung, A.; Afrough, A.; Rosiñol, L.; Yee, A. J.; more...
    Blood (2024)

    Fulltext@MSK | Save